Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Tuesday. The stock had previously closed at $15.36, but opened at $15.89. Ascentage Pharma Group International shares last traded at $15.49, with a volume of 983 shares traded.

Analyst Upgrades and Downgrades

AAPG has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citigroup initiated coverage on Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target on the stock. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective for the company. William Blair initiated coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. reduced their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $43.44.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The company’s 50 day simple moving average is $15.52 and its 200 day simple moving average is $19.83.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million during the quarter. As a group, sell-side analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.